Structure Therapeutics specializes in the discovery and development of drugs against a type of targets called GPCR.

Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team‚Äôs deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

Structure Therapeutics

Associate Director, Program Management

revmed

Kura Oncology, a biopharmaceutical company, advances a pipeline of precision medicines for the treatment of solid tumors and blood cancers.

At Kura Oncology, They are committed to realizing the promise of precision medicines for cancer. The genomics revolution is transforming how they treat cancer. They now understand that how a patient responds to treatment depends in part on the genetic makeup of the cancer and, importantly, we have the knowledge and tools to create targeted treatments and companion diagnostics to identify those patients most likely to benefit. This new era offers the potential for innovative treatments that are safer and more effective for patients with particular cancers. They are leveraging our insights into cancer genetics as well as our core strength of translating novel science into life-saving medicines to advance a pipeline of precision medicines. Their development programs target cancers with high unmet need, including lung, colorectal, thyroid and pancreatic cancers as well as blood cancers such as lymphoma and leukemias.

Kura Oncology

Associate Director, Global Program Management

Maravai is a life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines.

Maravai LifeSciences was formed in March 2014 as a partnership among Carl Hull and Eric Tardif -- proven leaders in the life sciences industry -- and GTCR, a leading private equity firm. Maravai‚Äôs mission is to build a transformative life sciences products company by acquiring outstanding businesses and accelerating their growth. They do this through direct cash investments in their existing operations, by acquiring complementary businesses or product lines and by contributing our proven operating expertise.

Maravai Life Sciences

Pandora provides internet radio and recommendation services.

Pandora is the world‚Äôs most powerful music discovery platform, offering a personalized experience for each of our listeners wherever and whenever they want to listen to music‚Äîwhether through mobile devices, car speakers or connected devices in the home. Unlike traditional radio that broadcasts the same content at the same time to all of its listeners, we enable our listeners to create personalized stations and playlists, as well as search and play songs and albums on-demand. The Music Genome Project, our content programming algorithms and data collected from our listeners power our ability to predict listener music preferences, play music content suited to the tastes of each individual listener and introduce listeners to the music we think they will love. Founded by musicians, Pandora also empowers artists with valuable data and tools to help grow their audience and connect with their fans. Pandora is available as an ad-supported radio service, a radio subscription service called Pandora Plus and an on-demand subscription service called Pandora Premium. The majority of our listener hours occur on mobile devices, with the majority of our revenue generated from advertising on our ad-supported radio service on these devices. With billions of data points that help us understand our users' preferences, we offer both local and national advertisers the opportunity to deliver targeted messages to our listeners using a combination of audio, display and video advertisements. We also generate increasing revenue from our subscription offerings.

Pandora

h1[itemprop="title"]

Associate Director, Program Management - SXM Product

Pliant Therapeutics focuses on discovering, developing, and commercializing breakthrough treatments for fibrotic diseases.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of av√ü6 and av√ü1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of av√ü1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.

Pliant Therapeutics

Valo Health uses human-centric data and machine learning-anchored computation to transform the drug discovery and development process.

Valo Health, LLC (Valo) is a technology company that is using human-centric data and machine learning-anchored computation to transform the drug discovery and development process. By integrating data across the drug development lifecycle, the discovery and development of life-changing treatments can be accelerated, with the potential to reduce cost, time, and failure rate. The company's Opal Computational Platform‚Ñ¢, a fully integrated, componentized, end-to-end drug development platform, offers a unique approach to therapeutic development, that enables Valo to advance a robust pipeline of candidates across cardiovascular disease, oncology, and neurodegeneration.

Valo Health

Associate Director, Portfolio & Program Management

TARA Biosystems Harnessing Human Biology + Data to Transform Cardiac Drug Discovery

Tara Biosystems provides predictive, in vitro human cardiac tissue models for use in drug discovery, safety assessment and translational medicine. Tara Biosystems offers a high-fidelity solution that is based on human stem cell-derived cardiac tissue matured to physiologically relevant adult-like levels and provides direct measures of cardiac functionality, including contractile force. The company is dedicated to pioneering predictive cardiac tissue models that enable the faster, safer, and more reliable development of new medicines.

Location

Company Stage

Age of Data

Experience

Industry

Company

Associate Director, Program Management

Structure Therapeutics

$150k - $206k

$149,600 - $205,700

revmed

$160k - $200k

$160,000 - $200,000

Kura Oncology

$185k

$185,000

Maravai Life Sciences

$130k - $178k

$130,000 - $178,000

Pandora

$130k - $160k

$130,000 - $160,000

Pliant Therapeutics

$75k - $101k

$74,809 - $101,095

Valo Health

N/A

N/A

TARA Biosystems

N/A

N/A